Anthem Biosciences Ltd
Incorporated in 2006, Anthem Biosciences
Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]
- Market Cap ₹ 41,469 Cr.
- Current Price ₹ 738
- High / Low ₹ 802 / 702
- Stock P/E 81.9
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 30.7 %
- ROE 23.0 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 21.9%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 626 | 633 | 1,103 | 1,231 | 1,057 | 1,418 | 1,841 | |
| 454 | 451 | 695 | 666 | 626 | 912 | 1,151 | |
| Operating Profit | 172 | 182 | 408 | 566 | 431 | 505 | 690 |
| OPM % | 27% | 29% | 37% | 46% | 41% | 36% | 37% |
| 21 | 21 | 37 | 49 | 139 | 70 | 109 | |
| Interest | 18 | 20 | 17 | 10 | 9 | 9 | 9 |
| Depreciation | 61 | 62 | 62 | 58 | 64 | 81 | 78 |
| Profit before tax | 114 | 121 | 366 | 547 | 498 | 485 | 711 |
| Tax % | 32% | 23% | 26% | 26% | 23% | 23% | 29% |
| 77 | 93 | 271 | 406 | 386 | 375 | 506 | |
| EPS in Rs | 91.97 | 110.62 | 319.77 | 462.60 | 6.76 | 6.70 | 9.05 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 14% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 40% |
| 3 Years: | 8% |
| TTM: | 35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 27% |
| 3 Years: | 22% |
| Last Year: | 23% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 9 | 114 | 112 | 112 |
| Reserves | 323 | 413 | 693 | 1,347 | 1,628 | 1,821 | 2,361 |
| 192 | 159 | 100 | 35 | 115 | 173 | 113 | |
| 194 | 207 | 232 | 228 | 136 | 219 | 249 | |
| Total Liabilities | 718 | 787 | 1,034 | 1,619 | 1,993 | 2,324 | 2,836 |
| 316 | 306 | 361 | 329 | 449 | 478 | 624 | |
| CWIP | 12 | 50 | 19 | 153 | 143 | 156 | 58 |
| Investments | 73 | 99 | 209 | 273 | 499 | 472 | 533 |
| 318 | 333 | 444 | 865 | 902 | 1,219 | 1,620 | |
| Total Assets | 718 | 787 | 1,034 | 1,619 | 1,993 | 2,324 | 2,836 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 196 | 166 | 278 | 333 | 319 | 164 | 440 | |
| -121 | -109 | -196 | -206 | -378 | -192 | -246 | |
| -65 | -48 | -63 | 181 | 53 | -132 | -66 | |
| Net Cash Flow | 9 | 9 | 18 | 308 | -6 | -159 | 127 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 61 | 84 | 97 | 95 | 126 | 89 |
| Inventory Days | 123 | 186 | 29 | 52 | 139 | 129 | 167 |
| Days Payable | 72 | 87 | 50 | 58 | 77 | 61 | 54 |
| Cash Conversion Cycle | 119 | 160 | 63 | 91 | 157 | 194 | 201 |
| Working Capital Days | 22 | 20 | 27 | 75 | 114 | 129 | 128 |
| ROCE % | 26% | 55% | 51% | 28% | 25% | 31% |
Documents
Announcements
-
Intimation Under Regulation 30(5) Of The SEBI (Listing Obligation And Disclosures Requirements) Regulation, 2015
21 Jul - Authorized key managerial personnel for materiality determination and disclosures under SEBI LODR.
-
Announcement Under Regulation 7(1) Of The SEBI (Listing Obligation And Disclosures Requirements) Regulation, 2015
21 Jul - Kfin Technologies appointed as Registrar & Share Transfer Agent for Anthem Biosciences.
-
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
21 Jul - Anthem Biosciences files SEBI insider trading code and fair disclosure procedures as per regulations.
- Closure of Trading Window 21 Jul
-
Appointment of Company Secretary and Compliance Officer
21 Jul - Ms. Divya Prasad continues as Compliance Officer of Anthem Biosciences as of Oct 18, 2024.
Business Overview:[1]
ABL is a Contract Research, Development,
and Manufacturing Organization with fully integrated operations across the drug discovery, development, and manufacturing value chain. It is among the few companies in India offering capabilities in both New Chemical
Entity (NCE) and New Biological Entity (NBE) programs. The company has developed various platforms such as RNA interference (RNAi),
Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides.